These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 26477842)

  • 61. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
    Enders P; Sitnilska V; Altay L; Fauser S
    Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
    Holz FG; Dugel PU; Weissgerber G; Hamilton R; Silva R; Bandello F; Larsen M; Weichselberger A; Wenzel A; Schmidt A; Escher D; Sararols L; Souied E
    Ophthalmology; 2016 May; 123(5):1080-9. PubMed ID: 26906165
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD.
    Roberts P; Mittermueller TJ; Montuoro A; Sulzbacher F; Munk M; Sacu S; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6623-30. PubMed ID: 25190663
    [TBL] [Abstract][Full Text] [Related]  

  • 66. RETROSPECTIVE REVIEW OF LUCENTIS "TREAT AND EXTEND" PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION.
    Chen YN; Powell AM; Mao A; Sheidow TG
    Retina; 2016 Feb; 36(2):272-8. PubMed ID: 26200511
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
    Scoles D; Ying GS; Pan W; Hua P; Grunwald JE; Daniel E; Jaffe GJ; Toth CA; Martin DF; Maguire MG;
    JAMA Ophthalmol; 2020 Mar; 138(3):276-284. PubMed ID: 31999297
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 70. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
    Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
    Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
    [TBL] [Abstract][Full Text] [Related]  

  • 74. INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Prospective Pilot Study.
    Barikian A; Salti H; Safar A; Mahfoud ZR; Bashshur ZF
    Retina; 2017 Jul; 37(7):1337-1344. PubMed ID: 27768640
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.
    Modarres M; Naseripour M; Falavarjani KG; Nikeghbali A; Hashemi M; Parvaresh MM
    Retina; 2009 Mar; 29(3):319-24. PubMed ID: 19287288
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
    Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
    Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
    ; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL
    Ophthalmology; 2012 Jul; 119(7):1388-98. PubMed ID: 22555112
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.